LadRx (OTCMKTS:CYTR) & Cabaletta Bio (NASDAQ:CABA) Head to Head Review

Cabaletta Bio (NASDAQ:CABA) and LadRx (OTCMKTS:CYTR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Cabaletta Bio and LadRx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	0	0	9	0	3.00
LadRx	0	0	0	0	N/A

Cabaletta Bio currently has a consensus target price of $30.11, indicating a potential upside of 584.34%.

Profitability

This table compares Cabaletta Bio and LadRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-43.98%	-40.68%
LadRx	N/A	-67.61%	-45.39%

Valuation and Earnings

This table compares Cabaletta Bio and LadRx’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$67.68 million	($1.71)	-2.57
LadRx	N/A	N/A	-$6.70 million	($0.15)	N/A

Cabaletta Bio is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cabaletta Bio has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500. Comparatively, LadRx has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500.

Insider and Institutional Ownership

0.1% of LadRx shares are held by institutional investors. 9.9% of Cabaletta Bio shares are held by insiders. Comparatively, 12.8% of LadRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

LadRx beats Cabaletta Bio on 5 of the 9 factors compared between the two stocks.

About Cabaletta Bio

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

About LadRx

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.